Emergex and Brazil's IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates - Brazil Business Today
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic
Source: einnews.com